A case of type IV solar urticaria identified by reverse in vitro serum test.
We had a 17-year-old male patient with solar urticaria diagnosed as type IV of modified Harber's classification. The action spectrum of this case was estimated to be 433-499 nm and the inhibition spectrum was 533 nm. Both in vitro serum test and tentatively designated "reverse in vitro serum test" were positive. The patient was prescribed 20 mg/day epinastine hydrochloride (Alesion) orally for 49 weeks with improvement of the symptoms.
Ozaki
Hirotake
H
Department of Dermatology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Matsuyama
Takashi
T
Kawakubo
Yo
Y
Miyahara
Motomi
M
Ozawa
Akira
A
D000284:Administration, Oral; D000293:Adolescent; D001769:Blood / Q000276:immunology / Q000528:radiation effects; D003984:Dibenzazepines / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006634:Histamine H1 Antagonists / Q000008:administration & dosage; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007271:Injections, Intradermal; D008297:Male; D010787:Photosensitivity Disorders / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D013472:Sunlight / Q000009:adverse effects*; D014581:Urticaria / Q000175:diagnosis* / Q000209:etiology*
D003984:Dibenzazepines; D006634:Histamine H1 Antagonists; D007093:Imidazoles; C053090:epinastine